NEWS - Centocor submits application to FDA to expand Simponi label in treatment of RA

[Guest guest]

Centocor Ortho Biotech Inc. Submits Application To FDA Seeking To

Expand SIMPONI® Label In Treatment Of Rheumatoid Arthritis

MedicalNewsToday.com

Article Date: 28 Sep 2010 - 0:00 PDT

Centocor Ortho Biotech Inc. announced today that it has submitted a

supplemental Biologics License Application (sBLA) to the U.S. Food and

Drug Administration (FDA) seeking to expand the SIMPONI® (golimumab)

physician label to include inhibiting the progression of structural

damage, inducing major clinical response (MCR) and maintenance of

reducing signs and symptoms and improving physical function in the

treatment of moderately to severely active rheumatoid arthritis (RA).

***********************************

Read the whole article here:

http://www.medicalnewstoday.com/articles/202618.php

Not an MD